Soluble complement receptor type I limits damage during revascularization of ischemic myocardium

Area of Science:

• Cardiovascular Research
• Immunology
• Ischemia-Reperfusion Injury

Background:

• Myocardial revascularization can trigger complement activation, leading to further tissue damage.
• Investigating methods to suppress complement activation is crucial for improving outcomes in ischemic heart disease.

Purpose of the Study:

• To evaluate the efficacy of soluble human complement receptor type I (sCR1) in mitigating myocardial damage during revascularization of ischemic myocardium.
• To determine if sCR1 suppresses complement activation and reduces infarct size in a porcine model.

Main Methods:

• A porcine model of myocardial ischemia (90 minutes) and reperfusion (180 minutes) was used.
• Soluble human complement receptor type I (sCR1) was administered to one group prior to ischemia, while a control group received no treatment.
• Complement activation, myocardial acidosis, wall motion, and infarct size were assessed.

Main Results:

• Hearts treated with sCR1 exhibited significantly reduced complement activation compared to controls (1.1% vs. 7.8%).
• sCR1 treatment led to less myocardial acidosis, improved wall motion scores, and a smaller infarct size (24.6% vs. 41%).
• These findings were statistically significant (p < 0.0001 for most parameters).

Conclusions:

• Complement inhibition with sCR1 effectively limits myocardial damage during acute ischemia and reperfusion.
• sCR1 demonstrates therapeutic potential in protecting the heart during revascularization procedures.
• Targeting complement activation is a viable strategy to reduce infarct size and improve cardiac function post-ischemia.